Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by stanleyon May 25, 2012 9:38am

165 Views

Post# 19945549

RE: Can anyone assist........?? TSX Only

Terry:

While the short history is interesting, the co-incident financing & and associated activity was worth watching. Alas, the price of oil SHOULD have an impact on the cost of production for the inputs of: transportation, explosives,fuels & lubes, etc. Thus a good purchasing agent will watch the "fuel surchage" part of an invoice(s) for ways to reduce production cost per ounce.

Any drill results owed the market? Did WD make any promises re drilling announcements at a recent CC?

BWDIK?

Cheers

Stanley

Bullboard Posts

Soma Gold poised to extend profitable track record